Indacaterol/glycopyrronium/mometasone (Enerzair Breezhaler) recommended for restricted use within NHS Wales

Recommended as an option for maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high dose of an inhaled corticosteroid who experienced 1 or more asthma exacerbations in the previous year.

All Wales Medicines Strategy Group